Pharmacological management of obesity: An endocrine society clinical practice guideline

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 2, 2015, Pages 342-362

  Apovian, Caroline M ^a   Aronne, Louis J ^b   Bessesen, Daniel H ^c   McDonnell, Marie E ^d   Murad, M Hassan ^e   Pagotto, Uberto ^f   Ryan, Donna H ^g   Still, Christopher D ^h  

^a BOSTON MEDICAL CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c DENVER HEALTH MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^h GEISINGER HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; AMFEBUTAMONE; AMFEPRAMONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; INCRETIN; INSULIN; LIRAGLUTIDE; LORCASERIN; METFORMIN; NALTREXONE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENTERMINE RESIN; PIOGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; TOPIRAMATE; UNINDEXED DRUG;

ARTICLE; CALORIC INTAKE; COMORBIDITY; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG MECHANISM; DRUG SAFETY; ENERGY EXPENDITURE; EVIDENCE BASED MEDICINE; HUMAN; LIFESTYLE MODIFICATION; MEDICAL SOCIETY; NEUROENDOCRINE DISEASE; NONHUMAN; OBESITY; OFF LABEL DRUG USE; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT INDICATION; TREATMENT RESPONSE; WEIGHT CONTROL; WEIGHT GAIN; WEIGHT REDUCTION; ENDOCRINOLOGY;

ENDOCRINOLOGY; EVIDENCE-BASED MEDICINE; HUMANS; OBESITY;

EID: 84922570654     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-3415     Document Type: Article

References (153)

1. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004; 328: 1490.
2. Swiglo BA, Murad MH, Schünemann HJ, et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab. 2008; 93: 666-673.
3. Domecq JP, Prutsky G, Leppin A, et al. Drugscommonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015; 100: 363-370.
4. Stacey D, Légaré F, Col NF, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2014; 1: CD001431.
5. American Medical Association. Policy H-440.842. Recognition of Obesity as a Disease; 2013.
6. Allison DB, Downey M, Atkinson RL, et al. Obesity as a disease: a white paper on evidence and arguments commissioned by the Council of the Obesity Society. Obesity (Silver Spring). 2008; 16: 1161-1177.
7. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl JMed. 2003; 348(17): 1625-1638.
8. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014; 129(25 suppl 2): S102-S138.
9. Rosenbaum M, Goldsmith R, Bloomfield D, et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest. 2005; 115: 3579-3586.
10. Hinkle W, Cordell M, Leibel R, Rosenbaum M, Hirsch J. Effects of reduced weight maintenance and leptin repletion on functional connectivity of the hypothalamus in obese humans. PLoS One. 2013; 8: e59114.
11. Goldsmith R, Joanisse DR, Gallagher D, et al. Effects of experimental weight perturbation on skeletal muscle work efficiency, fuel utilization, and biochemistry in human subjects. Am J Physiol Regul Integr Comp Physiol. 2010; 298: R79-R88.
12. Rosenbaum M, Hirsch J, Gallagher DA, Leibel RL. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. Am J Clin Nutr. 2008; 88: 906-912.
13. Pasman WJ, Saris WH, Muls E, Vansant G, Westerterp-Plantenga MS. Effect of exercise trainingon long-term weight maintenance in weight-reduced men. Metabolism. 1999; 48(1): 15-21.
14. Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011; 365: 1597-1604.
15. Farooqi IS, Wangensteen T, Collins S, et al. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med. 2007; 356(3): 237-247.
16. Leibel RL Molecular physiology of weight regulation in mice and humans. Int J Obes (Lond). 2008; 32(Suppl. 7): S98-S108.
17. Yu JH, Kim MS. Molecular mechanisms of appetite regulation. Diabetes Metab J. 2012; 36: 391-398.
18. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature. 2006; 443: 289-295.
19. Stahl SM Impulsivity, compulsivity, and addiction. In: Stahl's Essential Psychopharmacology. 4th ed. New York, NY: Cambridge University Press; 2013: 537-575.
20. Lutter M, Nestler EJ. Homeostatic and hedonic signals interact in the regulation of food intake. J Nutr. 2009; 139: 629-632.
21. Volkow ND, Wang GJ, Tomasi D, Baler RD. Obesity and addiction: neurobiological overlaps. Obes Rev. 2013; 14: 2-18.
22. Mendieta-Zerón H, López M, Diéguez C. Gastrointestinal peptides controlling body weight homeostasis. Gen Comp Endocrinol. 2008; 155: 481-495.
23. Cone RD Anatomy and regulation of the central melanocortin system. Nat Neurosci. 2005; 8: 571-578.
24. Korner J, Leibel RL. To eat or not to eat - how the gut talks to the brain. N Engl J Med. 2003; 349: 926-928.
25. Kim GW, Lin JE, Blomain ES, Waldman SA. Antiobesity pharma-cotherapy: new drugs and emerging targets. Clin Pharmacol Ther. 2014; 95: 53-66.
26. Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phenter-mine/topiramate extended-release in obese adults. Obesity (Silver Spring). 2013; 21: 2163-2171.
27. Carroll FI, Blough BE, Mascarella SW, Navarro HA, Lukas RJ, Damaj MI. Bupropion and bupropion analogs as treatments for CNS disorders. Adv Pharmacol. 2014; 69: 177-216.
28. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized, controlled trial. JAMA. 1999; 281: 235-242.
29. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004; 27(1): 155-161.
30. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013; 37: 1443-1451.
31. Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) [Errata (2012) 36: 890 and (2013) 37: 322]. 2012; 36: 843-854.
32. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013; 159: 262-274.
33. Wadden TA, Berkowitz RI, Sarwer DB, Prus-Wisniewski R, Steinberg C. Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. Arch Intern Med. 2001; 161: 218-227.
34. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014; 311: 74-86.
35. Avenell A, Brown TJ, McGee MA, et al. What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. J Hum Nutr Diet. 2004; 17: 293-316.
36. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005; 353: 2111-2120.
37. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrex-one SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011; 19: 110-120.
38. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001; 344: 1343-1350.
39. Hamman RF, Wing RR, Edelstein SL, et al. Effect of weight loss with lifestyle intervention on risk ofdiabetes. Diabetes Care. 2006; 29: 2102-2107.
40. Unick JL, Beavers D, Jakicic JM, et al. Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes: results from the Look AHEAD trial. Diabetes Care. 2011; 34: 2152-2157.
41. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012; 95: 297-308.
42. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011; 96: 3067-3077.
43. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, con-trolled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011; 377: 1341-1352.
44. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010; 363: 245-256.
45. O'Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012; 20: 1426-1436.
46. Qsymia (phentermine and topiramate extended-release) [prescribing information]. Mountain View, CA: Vivus Inc. http://www.qsymia.com/pdf/prescribing-information.pdf. Accessed July 2, 2014.
47. Xenical (orlistat) [prescribing information]. South San Francisco, CA: Genentech USA Inc. http://www.gene.com/download/pdf/xenical-prescribing.pdf. Accessed July 2, 2014.
48. Alli (orlistat) [label]. Moon Township, PA: Glaxo Smith Kline. http://www.accessdata.fda.gov/drugsatfda-docs/label/2007/021887lbl.pdf. Approved February 7, 2007. Accessed July 2, 2014.
49. Belviq (lorcaserin) [prescribing information]. Zofingen, Switzerland: Arena Pharmaceuticals GmbH. https://www.belviqhcp.com/media/1001/belviq-prescribing-information.pdf. Accessed July 2, 2014.
50. Fanghänel G, Cortinas L, Sánchez-Reyes L, Berber A. Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over. Int J Obes Relat Metab Disord. 2001; 25: 741-747.
51. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998; 352: 167-172.
52. Anderson JW, Schwartz SM, Hauptman J, et al. Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial. Ann Pharmacother. 2006; 40: 1717-1723.
53. Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord. 2002; 26: 262-273.
54. Li D, Morris JS, Liu J, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA. 2009; 301: 2553-2562.
55. Avenell A, Broom J, Brown TJ, et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess. 2004; 8: iii-iv, 1-182.
56. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term phar-macotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007; 335(7631): 1194-1199.
57. Leblanc ES, O'Connor E, Whitlock EP, Patnode CD, Kapka T. Effectiveness of primary care-relevant treatments for obesity in adults: asystematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011; 155: 434-447.
58. Maahs D, de Serna DG, Kolotkin RL, et al. Randomized, doubleblind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract. 2006; 12: 18-28.
59. McDuffie JR, Calis KA, Booth SL, Uwaifo GI, Yanovski JA. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy. 2002; 22: 814-822.
60. McGovern L, Johnson JN, Paulo R, et al. Clinical review: treatment of pediatric obesity: a systematic review and meta-analysis of randomized trials. J Clin Endocrinol Metab. 2008; 93: 4600-4605.
61. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012; 20: 330-342.
62. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011; 10: CD006423.
63. Malin SK, Kashyap SR. Effects of metformin on weight loss: potential mechanisms. Curr Opin Endocrinol Diabetes Obes. 2014; 21(5): 323-329.
64. Caton PW, Kieswich J, Yaqoob MM, Holness MJ, Sugden MC. Metformin opposes impaired AMPK and SIRT1 function and deleterious changes in core clock protein expression in white adipose tissue of genetically-obese db/db mice. Diabetes Obes Metab. 2011; 13(12): 1097-1104.
65. Chapman I, Parker B, Doran S, et al. Effect of pramlintideon satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia. 2005; 48(5): 838-848.
66. Smith SR, Blundell JE, Burns C, et al. Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. Am J Physiol Endocrinol Metab. 2007; 293(2): E620-E627.
67. Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012; 97: 1020-1031.
68. Grandy S, Hashemi M, Langkilde AM, Parikh S, Sjöström CD. Changesin weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin. Diabetes Obes Metab. 2014; 16: 645-650.
69. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346: 393-403.
70. Wainstein J, Katz L, Engel SS, et al. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2012; 14(5): 409-418.
71. Horton ES, Silberman C, Davis KL, Berria R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care. 2010; 33: 1759-1765.
72. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009; 373(9662): 473-481.
73. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2008; 2: CD006739.
74. Wu D, Li L, Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Obes Metab. 2014; 16(1): 30-37.
75. Scheen AJ DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab. 2012; 38: 89-101.
76. McIntosh B, Cameron C, Singh SR, et al. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med. 2011; 5: e35-e48.
77. Singh-Franco D, Perez A, Harrington C. The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2011; 13: 169-180.
78. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012; 8: 495-502.
79. Greenway FL, Fujioka K, Plodkonski RA, et al. COR I Study Group. Lancet. 2010; 376: 595-605.
80. McDonnell ME Combination therapy with new targets in type 2 diabetes: a review of available agents with a focus on pre-exercise adjustment. J Cardiopulm Rehabil Prev. 2007; 27: 193-201.
81. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32: 193-203.
82. Jacob AN, Salinas K, Adams-Huet B, Raskin P. Weight gainintype 2 diabetes mellitus. Diabetes Obes Metab. 2007; 9: 386-393.
83. Raslová K, Tamer SC, Clauson P, Karl D. Insulin detemir results in lessweight gain than NPH insulin whenusedinbasal-bolustherapy for type2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Investig. 2007; 27: 279-285.
84. Hermansen K, Davies M. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab. 2007; 9: 209-217.
85. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007; 357: 1716-1730.
86. Goudswaard AN, Furlong NJ, Rutten GE, Stolk RP, Valk GD. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2004; 4: CD003418.
87. Chow CC, Tsang LW, Sorensen JP, Cockram CS. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care. 1995; 18: 307-314.
88. Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus. Diabetologia. 1999; 42: 406-412.
89. Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003; 26: 784-790.
90. Aronne L, Fujioka K, Aroda V, et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab. 2007; 92: 2977-2983.
91. Hollander P, Raslova K, Skjøth TV, Råstam J, Liutkus JF. Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial. Diabetes Obes Metab. 2011; 13: 268-275.
92. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011; 154: 103-112.
93. Contrave [package insert]. Deerfield, IL: Takeda Pharmaceuticals USA Inc. http://general.takedapharm.com/content/file.aspx?filetypecode=CONTRAVEPI&CountryCode=US&LanguageCode=EN&cacheRandomizer=bc8d4bba-8158-44f2-92b3-1e1ba338af0a. Accessed January 5, 2015.
94. Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009; 361: 1736-1747.
95. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003; 348: 583-592.
96. Manrique C, Whaley-Connell A, Sowers JR. Nebivolol in obese and non-obese hypertensive patients. J Clin Hypertens (Greenwich). 2009; 11: 309-315.
97. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. Hypothesis: β-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension. 2001; 37: 250-254.
98. Messerli FH, Bell DS, Fonseca V, et al. Body weight changes with β-blocker use: results from GEMINI. Am J Med. 2007; 120: 610-615.
99. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010; 71: 1259-1272.
100. Rosenzweig-Lipson S, Beyer CE, Hughes ZA, et al. Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther. 2007; 113: 134-153.
101. Nutt DJ Tolerability and safety aspects of mirtazapine. Hum Psychopharmacol. 2002; 17(Suppl. 1): S37-S41.
102. Weber E, Stack J, Pollock BG, et al. Weight change in older depressed patients during acute pharmacotherapy with paroxetine and nortriptyline: a double-blind randomized trial. Am J Geriatr Psychiatry. 2000; 8: 245-250.
103. Gadde KM, Xiong GL. Bupropion for weight reduction. Expert Rev Neurother. 2007; 7: 17-24.
104. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001; 62(Suppl. 7): 22-31.
105. Kurzthaler I, Fleischhacker WW. The clinical implications of weight gain in schizophrenia. J Clin Psychiatry. 2001; 62(Suppl. 7): 32-37.
106. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry. 2000; 157: 975-981.
107. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of anti-psychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353: 1209-1223.
108. Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004; 161: 1837-1847.
109. Komossa K, Rummel-Kluge C, Hunger H, et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009; 4: CD006627.
110. Maayan L, Correll CU. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2011; 21: 517-535.
111. Ballon JS, Pajvani U, Freyberg Z, Leibel RL, Lieberman JA. Molecular pathophysiology of metabolic effects of antipsychotic medications. Trends Endocrinol Metab. 2014; 25(11): 593-600.
112. Ben-Menachem E. Weight issues for people with epilepsy - a review. Epilepsia. 2007; 48(Suppl. 9): 42-45.
113. Verrotti A, D'Egidio C, Mohn A, Coppola G, Chiarelli F. Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obes Rev. 2011; 12: e32-e43.
114. Corman CL, Leung NM, Guberman AH. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can J Neurol Sci. 1997; 24: 240-244.
115. DeToledo JC, Toledo C, DeCerce J, Ramsay RE. Changes inbody weight with chronic, high-dose gabapentin therapy. Ther Drug Monit. 1997; 19: 394-396.
116. Jallon P, Picard F. Bodyweight gain and anticonvulsants: a comparative review. Drug Saf. 2001; 24: 969-978.
117. Gaspari CN, Guerreiro CA. Modification in body weight associated with antiepileptic drugs. Arq Neuropsiquiatr. 2010; 68: 277-281.
118. Gallo MF, Lopez LM, Grimes DA, Carayon F, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochrane Database Syst Rev. 2014; 1: CD003987.
119. Lopez LM, Edelman A, Chen M, Otterness C, Trussell J, Helmerhorst FM. Progestin-only contraceptives: effects on weight. Cochrane Database Syst Rev. 2013; 7: CD008815.
120. Stricker RB, Goldberg B. Weight gain associated with protease inhibitor therapy in HIV-infected patients. Res Virol. 1998; 149: 123-126.
121. Reust CE Common adverse effects of antiretroviral therapy for HIV disease. Am Fam Physician. 2011; 83: 1443-1451.
122. Sutbeyaz ST, Sezer N, Koseoglu BF, Ibrahimoglu F, Tekin D. Influence of knee osteoarthritis on exercise capacity and quality of life in obese adults. Obesity. 2007; 15: 2071-2076.
123. Da Silva JA, Jacobs JW, Bijlsma JW. Revisiting the toxicity of low-dose glucocorticoids: risks and fears. Ann NY Acad Sci. 2006; 1069: 275-288.
124. Jacobs JW, Boers M, Kirwan JR, Bijlsma JW. The benefit of low-dose glucocorticoid treatment in early rheumatoid arthritis may outweigh the risk: comment on the editorial by Harris. Arthritis Rheum. 2006; 54(6): 2031-2032; author reply 2032.
125. Landewé RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 2002; 46: 347-356.
126. Boers M, van der Heijde DM. Prevention or retardation of joint damage in rheumatoid arthritis: issues of definition, evaluation and interpretation of plain radiographs. Drugs. 2002; 62(12): 1717-1724.
127. Prummel MF, Mourits MP, Blank L, Berghout A, Koornneef L, Wiersinga WM. Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Lancet. 1993; 342(8877): 949-954.
128. Aronne LJ Drug-induced weight gain: non-CNS medications. In: Aronne LJ, ed. A Practical Guide to Drug-Induced Weight Gain. Minneapolis, MN: McGraw-Hill; 2002: 77-91.
129. Ratliff JC, Barber JA, Palmese LB, Reutenauer EL, Tek C. Association of prescription H1 antihistamine use with obesity: results from the National Health and Nutrition Examination Survey. Obesity (Silver Spring). 2010; 18: 2398-2400.
130. Weintraub M, Sundaresan PR, Schuster B, et al. Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise. Clin Pharmacol Ther. 1992; 51: 595-601.
131. Hendricks EJ, Srisurapanont M, Schmidt SL, et al. Addiction potential of phentermine prescribed during long-term treatment of obesity. Int J Obes (Lond). 2014; 38: 292-298.
132. Cohen, RV, Pinheiro JC, Schiavon CA, Salles JE, Wajchenberg BL, Cummings DE. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care. 2012; 35: 1420-1428.
133. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012; 366: 1577-1585.
134. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012; 366: 1567-1576.
135. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009; 122: 248-256.e5.
136. Ilanne-Parikka P, Eriksson JG, Lindström J, et al. Effect of lifestyle interventionon the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care. 2008; 31: 805-807.
137. Phelan S, Wadden TA, Berkowitz RI, et al. Impact of weight loss on the metabolic syndrome. Int J Obes (Lond). 2007; 31: 1442-1448.
138. Zanella MT, Uehara MH, Ribeiro AB, Bertolami M, Falsetti AC, Yunes MA. Orlistat and cardiovascular risk profilein hypertensive patients with metabolic syndrome: the ARCOS study. Arq Bras Endocrinol Metabol. 2006; 50: 368-376.
139. Wannamethee SG, Shaper AG, Walker M. Overweight and obesity and weight change in middle aged men: impact on cardiovascular disease and diabetes. J Epidemiol Community Health. 2005; 59: 134-139.
140. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol. 1991; 12: 224-229.
141. Huang MA, Greenson JK, Chao C, et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol. 2005; 100: 1072-1081.
142. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalitiesin overweight patients. Gastroenterology. 1990; 99(5): 1408-1413.
143. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol. 1997; 27: 103-107.
144. Christensen R, Bartels EM, Astrup A, Bliddal H. Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2007; 66: 433-439.
145. Fransen M. Dietary weight loss and exercise for obese adults with knee osteoarthritis: modest weight loss targets, mild exercise, modest effects. Arthritis Rheum. 2004; 50: 1366-1369.
146. Huang MH, Chen CH, Chen TW, Weng MC, Wang WT, Wang YL. The effects of weight reduction on the rehabilitation of patients with knee osteoarthritis and obesity. Arthritis Care Res. 2000; 13: 398-405.
147. Messier SP, Loeser RF, Miller GD, et al. Exercise and dietary weight loss in overweight and obese older adults with knee osteoarthritis: the Arthritis, Diet, and ActivityPromotion Trial. Arthritis Rheum. 2004; 50: 1501-1510.
148. van Gool CH, Penninx BW, Kempen GI, et al. Effects of exercise adherence on physical function among overweight older adults with knee osteoarthritis. Arthritis Rheum. 2005; 53: 24-32.
149. Adams TD, Stroup AM, Gress RE, et al. Cancer incidence and mortality after gastric bypass surgery. Obesity. 2009; 17: 796-802.
150. Sjöström L, Gummesson A, Sjöström CD, et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 2009; 10: 653-662.
151. Kuna ST, Reboussin DM, Borradaile KE, et al. Long-term effect of weight loss on obstructive sleep apnea severity in obese patients with type 2 diabetes. Sleep. 2013; 36: 641-649A.
152. van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care. 2005; 28(1): 154-163.
153. Lee A, Patrick P, Wishart J, Horowitz M, Morley JE. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab. 202; 4(5): 329-335.